Sports nutrition supplements and adverse events – a meta-epidemiological study of case reports specifically addressing causality assessment Rickard ZeijlonVictor HanteliusLina Holmqvist Review Open access 02 October 2021 Pages: 1 - 9
The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers F. SchneiderD. StamlerL. Rabinovich-Guilatt Clinical Trial Open access 01 September 2021 Pages: 11 - 18
Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients Egle CorradoGiuseppe DattiloCesare de Gregorio Clinical Trial 23 September 2021 Pages: 19 - 25
Intravenous lidocaine vs. NSAIDs for migraine attack in the ED: a prospective, randomized, double-blind study Sultan Tuna Akgol GurElif Oral AhiskaliogluAli Ahiskalioglu Clinical Trial 16 September 2021 Pages: 27 - 33
Proton pump inhibitors and osteoporosis risk: exploring the role of TRPM7 channel Bhargavi V. DesaiMisbah N. QadriBhavin A. Vyas Pharmacodynamics 29 October 2021 Pages: 35 - 41
To establish a model for the prediction of initial standard and maintenance doses of warfarin for the Han Chinese population based on gene polymorphism: a multicenter study Xiaotong XiaNianxu HuangJinhua Zhang Pharmacogenetics 28 August 2021 Pages: 43 - 51
Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites Zheng LiuJennifer H. MartinMichael Michael Pharmacogenetics 04 September 2021 Pages: 53 - 64
Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment Akiko WatanabeTomoko IshizukaHitoshi Ishizuka Pharmacokinetics and Disposition Open access 20 August 2021 Pages: 65 - 73
Correction to: Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment Akiko WatanabeTomoko IshizukaHitoshi Ishizuka Correction 08 September 2021 Pages: 75 - 75
Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients Kazuki AbeKaito ShibataJunichi Kawakami Pharmacokinetics and Disposition 19 August 2021 Pages: 77 - 87
Population pharmacokinetics-pharmacodynamics of fondaparinux in dialysis-dependent chronic kidney disease patients undergoing chronic renal replacement therapy Danica MichaličkováJan Miroslav HartingerElke H. J. Krekels Pharmacokinetics and Disposition 19 August 2021 Pages: 89 - 98
Correction to: Population pharmacokinetics‑pharmacodynamics of fondaparinux in dialysis‑dependent chronic kidney disease patients undergoing chronic renal replacement therapy Danica MichaličkováJan Miroslav HartingerElke H. J. Krekels Correction 16 September 2021 Pages: 99 - 99
Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking Anna Basińska-Szafrańska Pharmacokinetics and Disposition Open access 13 September 2021 Pages: 101 - 110
Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials with GRADE qualification of available evidence Josip A. BorovacMette Leth-OlsenJosko Bozic Pharmacoepidemiology and Prescription 23 August 2021 Pages: 111 - 126
Improving medication adherence and effective prescribing through a patient-centered prescription model in patients with multimorbidity J. González-BuenoD. Sevilla-SánchezJ. Espaulella-Panicot Pharmacoepidemiology and Prescription 27 August 2021 Pages: 127 - 137
The impact of PIPs on mortality and readmissions in older adults: a retrospective cohort study Alfredo Jose Pardo-CabelloVictoria Manzano-GameroJuan de Dios Luna Pharmacoepidemiology and Prescription 16 September 2021 Pages: 139 - 145
Restrictions on the use of placebo in new COVID-19 vaccine trials Maurizio Bonati Point of View 30 August 2021 Pages: 147 - 148
Response/comments to maternal paracetamol intake and fetal ductus arteriosus closure: adding pieces to the scenery—Karel Allegaert, Michael Ceulemans, John van den Anke Manfred HaubenStephen BaiVincent P. Zucal Letter to the Editor 26 August 2021 Pages: 149 - 149
European NSTEMI guidelines—return of clopidogrel? Lisa DannenbergRené M’PembeleAmin Polzin Letter to the Editor Open access 15 September 2021 Pages: 151 - 153
CYP2D6 genetic variation in Ugandans Jun MiuraCelestino ObuaSunao Kaneko Letter to the Editor 27 August 2021 Pages: 155 - 157